Aker BioMarine signs first commercial agreement for LYSOVETA with Trofi Nutritionals to develop several medical foods products based on Lysoveta, targeting reproductive health and brain health, in addition to pre-natal supplements.
Aker BioMarine and nutraceutical company, Trofi Nutritional Inc. (Trofi), have entered into a license and supply agreement in executing clinical development and commercialization of medical food products targeting male infertility, gestational diabetes and Alzheimer’s disease, in addition to pre-natal supplements.
“These diseases have a severe impact on the lives for a large proportion of the population globally. The collaboration with Trofi is an important milestone in commercializing Lysoveta and will continue to build the body of scientific evidence for Lysoveta’s beneficial effects across life stages,” said Matts Johansen CEO, Aker BioMarine.
According to the Center for Disease Control and Prevention, CDC, there is an increase in these diseases in the US population. This is due to the fact that we are living longer with lifestyle related risk factors for these diseases. There are limited therapeutical options available in today’s healthcare system to address these conditions.
Lysoveta features essential nutrients such as Choline, EPA and DHA in the form of Lysophosphatidylcholine (LPC). These nutrients have an important role in the development and function of the brain. LPC has shown to efficiently target the brain and demonstrated improvement in short-term memory in pre-clinical trials.
” The latest science demonstrates that impairment of the MFSD2a transporter in certain diseases can result in DHA deficiency. Therefore, we believe that utilizing LYSOVETA as a clinically validated medical food will be well accepted by the physician community” said co-founder Dr. Michael Davidson. “The Trofi Lysoveta based nutritional solutions will have the potential to improve the quality of life for millions of people,” said Barbara McCartney CEO, Trofi Nutritionals.
Trofi is an early-stage pioneer in next-generation nutritional solutions designed to support a range of health needs from managing chronic conditions to achieving wellness goals. The company was co-founded by Dr. Michael Davidson, Clinical Professor of Medicine and Director of the Lipid Clinic at the University of Illinois, together with Jonathan Jonas, CEO of JVC investment Partners. Trofi is led by CEO Barbara McCartney, an accomplished multi-country leader in the nutrition and wellness space who has held business management roles with Nestle Health Science, Novartis Nutrition and Abbott Nutrition.
“The team at Trofi shares our understanding in the importance of Lysoveta based on the strong scientific foundation and preclinical data, substantiating their investment in clinical development,” said Christine Strømhylden Lunder, Venture Lead, Lysoveta.
Since the launch of Lysoveta in 2020, Aker BioMarine has signed several partnerships with leading scientific institutes in the field of brain health, such as University of Sherbrook and University of Illinois Chicago to expand the scientific knowledge base.
Under the agreement, Aker BioMarine will license, with associated royalties, relevant intellectual property rights and supply Lysoveta to Trofi, who will invest in clinical trials with the aim to develop and commercialize certain medical foods within the fields. Launch of first medical food and dietary supplement is planned for 2024.
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52
